Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 5,353 matching trials from the live ClinicalTrials.gov search.
Filters: Milwaukee, Wisconsin Clear all
Terminated No phase listed Observational

Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction

NCT01410071
View directory record Official record
Conditions
Sphincter of Oddi Dysfunction, Abdominal Pain
Interventions
Not listed
Lead sponsor
Wisconsin Center for Advanced Research
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 3 Interventional

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

NCT01204749
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
AMG 386, AMG 386 Placebo, Paclitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 28, 2026, 4:55 PM EDT
Terminated Phase 3 Interventional Results available

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

NCT01522443
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions
cabozantinib, mitoxantrone, prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
49
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 28, 2026, 4:55 PM EDT
Completed No phase listed Observational

Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling

NCT00677508
View directory record Official record
Conditions
Constipation, Fecal Incontinence
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

NCT00035815
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Insulin like growth factor, type 1, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
19
States / cities
Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 28, 2026, 4:55 PM EDT
Active, not recruiting Not applicable Interventional

(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds

NCT05364502
View directory record Official record
Conditions
Arterial Bleeding in Solid Organs and Peripheral Arteries
Interventions
Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter
Device
Lead sponsor
Instylla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Long Beach, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 28, 2026, 4:55 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

NCT07225972
View directory record Official record
Conditions
CMV, AdV Infection, AdV Reactivation, Adenovirus, Cytomegalovirus Infections
Interventions
Standard of Care Antiviral medications, Viral CTLs
Drug · Biological
Lead sponsor
New York Medical College
Other
Eligibility
1 Day to 30 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Valhalla, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

NCT01444430
View directory record Official record
Conditions
Asthma
Interventions
Symbicort pMDI, budesonide pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
160
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 3 Interventional

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241553
View directory record Official record
Conditions
NSAIDs, Upper GI Symptoms
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
31
States / cities
Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 28, 2026, 4:55 PM EDT
Recruiting Phase 1 Interventional

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019
View directory record Official record
Conditions
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions
SGR-1505
Drug
Lead sponsor
Schrödinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 28, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Saracatinib in Treating Patients With Prostate Cancer

NCT01267266
View directory record Official record
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
saracatinib, hydrocortisone/placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 28, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

NCT06649812
View directory record Official record
Conditions
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography, Prednisone, Venetoclax
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
114
States / cities
Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 4:55 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

NCT04973137
View directory record Official record
Conditions
Light Chain (AL) Amyloidosis
Interventions
Birtamimab, Placebo, Standard of Care Chemotherapy
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
22
States / cities
North Haven, Connecticut • Trumbull, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 28, 2026, 4:55 PM EDT
Recruiting Phase 3 Interventional

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

NCT07441681
View directory record Official record
Conditions
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cetuximab, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Survey Administration
Procedure · Drug · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
150
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 4:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

NCT03737981
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
65 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
857
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

NCT00596466
View directory record Official record
Conditions
Epilepsy
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822
View directory record Official record
Conditions
Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
Ciforadenant, Ciforadenant + atezolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Tucson, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 28, 2026, 4:55 PM EDT
Withdrawn Not applicable Interventional

Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux

NCT03463395
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Reza band
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

NCT00684983
View directory record Official record
Conditions
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Capecitabine, Cixutumumab, Lapatinib Ditosylate, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
390
States / cities
Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 274 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 28, 2026, 4:55 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437
View directory record Official record
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

NCT01852045
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 28, 2026, 4:55 PM EDT
Terminated No phase listed Observational

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

NCT05592483
View directory record Official record
Conditions
Breast Cancer
Interventions
None (Observational Study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
40
States / cities
Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 28, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

NCT04159831
View directory record Official record
Conditions
Pleural Effusion
Interventions
LTI-01, Placebo
Drug
Lead sponsor
Rein Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 28, 2026, 4:55 PM EDT